Board of Directors
Tim Harkness
President and Chief Executive Officer
Tim Harkness joined Cell Biosciences as President and CEO in June 2008. He brings more than 15 years of leadership experience in the life sciences industry. From 1998 through 2007, Tim was CFO of Molecular Devices (Nasdaq: MDCC), where he helped grow the company’s revenue from $38M to $185M before selling the company for $615M. At Molecular, Tim also oversaw the transfer of manufacturing to China as Senior VP of Operations and was responsible for directing the acquisition strategy of the company which resulted in over $95M in annual revenue. From 1997 to 1998 Tim was VP of Business Development at Vivra Specialty Partners, a private equity backed physician practice management company. From 1994 to 1997 Tim was in the Health Care Investment Banking group at Montgomery Securities where he helped raise over $1B for life sciences companies in the public equity markets. Tim started his career at Arthur Andersen in Minneapolis where he worked from 1989 to 1992. Mr. Harkness currently serves on the Board of Directors at Symyx Technologies (Nasdaq:SMMX), a scientific software company and at ForteBio, a private life science tools company. Mr. Harkness holds an M.B.A. from Stanford University Graduate School of Business, a B.B.A. from University of Wisconsin, and is a CPA. Tim is married with 3 children, enjoys running and golf, and is an avid sports fan.
A. Blaine Bowman
Lead Director
Mr. Bowman was most recently the President and Chief Executive Officer of Dionex Corporation (NASDAQ: DNEX), a leading developer and manufacturer of laboratory and process analytical systems and related products. Mr. Bowman joined the company in 1977. Under his leadership, Dionex grew from $1 million in sales to over $180 million and is widely respected for its innovative products and solid growth. Earlier, he was a management consultant with McKinsey and Company and a product engineer in Motorola Semiconductor Products Division. Mr. Bowman holds a B.S. Degree in Physics from Brigham Young University and an M.B.A. from Stanford University Graduate School of Business. Additionally, Mr. Bowman has served on the Board of Directors of Molecular Devices Corporation since 1992.
Jim Blair
Domain Associates
Mr. Blair has been a General Partner of Domain Associates since its founding in 1985. He has over thirty years experience with venture and emerging growth companies. In the course of this experience, he has been involved as a board member with the creation and successful development of over forty life science ventures including Amgen, Amylin Pharmaceuticals, Applied Biosystems, Aurora Biosciences, Dura Pharmaceuticals, Sicor, and Molecular Dynamics. Mr. Blair is presently an advisor to the Department of Molecular Biology at Princeton University, an Advisor to the Department of BioEngineering at the University of Pennsylvania, and he also serves on the Board of Directors of the Prostate Cancer Foundation.
Jim Woody, Ph.D.
Latterell Venture Partners
Dr. Woody brings more than 25 years of biomedical research and management experience to LVP. Dr. Woody was formerly President of Roche Bioscience in Palo Alto, California where he had responsibility for all bioscience research and development, ranging from genetics and genomics to clinical development. Previously, Dr. Woody served as Chief Scientific Officer and Senior Vice President of Research & Development for Centocor, where he was responsible for the discovery and early clinical development of antibody and peptide-based therapeutic products. While at Centocor, Dr. Woody developed Remicade®, the first of the TNF inhibitor biologics, as well as ReoPro®, a novel platelet blocking drug used in conjunction with angioplasty. Prior to Centocor, Dr. Woody served as Commanding Officer and Director, U.S. Naval Medical Research and Development Command in Bethesda, Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the U.S. Navy Legion of Merit for his service. Dr. Woody holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England.
David L. Barker, Ph.D.
Dr. David L. Barker currently serves on the Boards of Directors of Cell Biosciences, BIoNanomatrix, Integrated Diagnostics, IntegenX Inc., and NextBio, and is a scientific advisor to Illumina, GenVault, Diagnostics for the Real World, Helixis, BiOptix, and DNA Direct. He was Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 through 2006. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a B.S. with honors in Chemistry from the California Institute of Technology and a Ph.D. in Biochemistry from Brandeis University.
Julie Eskay-Eagle
The Wellcome Trust
Julie Eskay-Eagle is the Co-Head of Health Care and Venture Capital Investments for the Wellcome Trust, which manages over $20 billion in assets. Her responsibilities include managing direct investments in 18 venture investments in the life sciences sector as well as relationships with leading health care venture funds and investments totaling over $300 million in health care -specific public equity funds. Prior to joining the Trust Ms. Eskay-Eagle was a Vice President with Lazard Freres in Health Care Investment Banking and a founding member of Lazard Technology Partners. Before joining Lazard, she was a Health Care Specialist with McKinsey & Co. in New York. Ms. Eskay-Eagle has a bachelor’s degree in Biomedical Ethics from Cornell University and an M.B.A. from Columbia University. Ms. Eskay-Eagle is currently a director of Cell Biosciences, Sequoia Pharmaceuticals, Chroma Therapeutics and Amplimmune.
Jack Nielsen
Novo Ventures
Jack Nielsen is Partner in Novo Ventures, which he joined in 2001. From 1990 to 2001 Mr. Nielsen held various positions in the Novo Nordisk business area, which in 2000 became Novozymes A/S. The last four years before joining Novo Ventures he was deeply involved in designing the research and development strategy for the company's efforts in the Cereal Food area, resulting in the development and launch of novel recombinant lipase and amylase enzymes. Mr. Nielsen was previously involved in collaborations with Procter & Gamble, Danisco, and Quest International to identify new enzymes for the detergent and cereal food industry. He held positions in marketing and technical services in the textile and personal care area, and started his career in the field of large-scale manufacturing of enzymes. Mr. Nielsen serves on the boards of directors of Cell Biosciences, Inc., Protein Forest, Inc. and Reata Pharmaceuticals, Inc., and he is a former director of Panacos Pharmaceuticals, Inc., Nuevolution A/S, and CardioOptics, Inc.
Jack Nielsen obtained his M.Sc. in 1990 from the Technical University of Denmark, and his Master in Management of Technology from the Center for Technology, Economics and Management in Copenhagen in 2000.
|
